

CRITICAL REVIEWS™ IN ONCOGENESIS

INDEX VOLUME 30, 2025

Page Range of Issues:

Issue 1: 1–135; Issue 2: 1–106; Issue 3: 1–108; Issue 4: 1–97

ISSUE 1

Special Issue: Targeted Innovations in Cancer Therapy: Molecular Interactions in Protein-Protein and Protein-Ligand Dynamics

Guest Editors: Kallimakula Venkatareddy Saritha & Ganji Purnachndra Nagaraju

Benjamin Bonavida Bio	v
Kallimakula Venkatareddy Saritha Bio	vii
Ganji Purnachndra Nagaraju Bio	ix
Preface <i>K.V. Saritha & G.P. Nagaraju</i>	xi
Molecular Docking: An Emerging Tool for Target-Based Cancer Therapy <i>P. Uppathi, S. Rajakumari, & K.V. Saritha</i>	1
Machine Learning Approaches for Neuroblastoma Risk Prediction and Stratification <i>R. Vadde & M.K. Gupta</i>	15
Interaction of Heat Shock Protein 90 (HSP90), Ganetespib, and 5-Fluorouracil by Computational Approach for Colorectal Cancer Therapy <i>Y. Golivi, S.K. Behera, A. Alam, & S. Peela</i>	31
Investigation of Benzimidazole Derivatives in Molecular Targets for Breast Cancer Treatment: A Comprehensive Review <i>P. Katiyar, Kalpana, A. Srivastava, & C.M. Singh</i>	43
Identification of Glucose-6-Phosphate Dehydrogenase (G6PD) Inhibitors by Cheminformatics Approach <i>S. Mundla & M.S. Saddala</i>	59
Coralyne Targets the Catalytic Domain of MMP9: An <i>In Silico</i> and <i>In Vitro</i> Investigation <i>R.K. Vempati & R.R. Malla</i>	71
Molecular Dynamics of Adenomatous Polyposis Coli (APC) Protein and Its Inhibitors: A Special Insight to Colorectal Cancer <i>R. Kumari, D. Ghava, R. Rathod, A.K. Panda, S. Kumar, & S.K. Behera</i>	91
Targeting Breast Adenocarcinoma with <i>Grangea maderaspatana</i> Natural Compounds: A Molecular Docking and Pharmacokinetic Study <i>S. Rajakumari, P. Uppathi, & K.V. Saritha</i>	107
<i>In Silico</i> Analysis of Anti-Cancer Activity of Exopolysaccharide Isolated from Novel <i>Pseudolagarobasidium acaciicola</i> through Mass Production, Gel Permeation Separation, and Compositional Analysis <i>S. Behera & N. Gupta</i>	119

ISSUE 2

Special Issue: Probiotics, Microbiota and Oncogenesis

Guest Editors: Luca Falzone, Benjamin Bonavida, & Massimo Libra

Benjamin Bonavida Bio	v
Luca Falzone Bio	vii
Massimo Libra Bio	ix
Preface: Probiotics and Implications in Oncogenesis <i>B. Bonavida, L. Falzone, & M. Libra</i>	xi
Review Article: Understanding the Role of the Microbiome in Breast Cancer Progression <i>S. Kumari, M. Srilatha, & G.P. Nagaraju</i>	1

Review Article: Involvement of the Gut Microbiome and Probiotic Interventions in Pediatric Acute Lymphoblastic Leukemia	13
<i>I. Navasardyan</i>	
Review Article: Fecal Microbiota Transplantation in Melanoma: Mechanisms-Mediated Enhancement of Anti-Tumor Immunotherapy	23
<i>W. Ung & B. Bonavida</i>	
Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer	37
<i>M. Ho & B. Bonavida</i>	
Review Article: Probiotics and Oncogenesis: Clinical Implications	49
<i>B.K. Leyva & B. Bonavida</i>	
Review Article: Night Shift Work, Circadian Disruption, and the Gut Microbiome: Implications for Human Health	67
<i>S. Vivarelli, A. Marconi, S. Matera, L. Falzone, & C. Fenga</i>	
Review Article: Disrupted Oral Microbiota and Its Implications in Cancer Onset and Progression: A Narrative Review	83
<i>G. Cultrera, S. Franco, G. Spoto, M. Libra, & L. Falzone</i>	

ISSUE 3

SPECIAL ISSUE: TARGETING ANTIAPOPTOTIC MECHANISMS IN CANCER: CLINICAL AND TRANSLATIONAL PERSPECTIVES

GUEST EDITORS: RIYAZ BASHA & GANJI PURNACHANDRA NAGARAJU

Benjamin Bonavida Bio	v
Riyaz Basha Bio	vii
Ganji Purnachandra Nagaraju Bio	ix
Preface	xi
<i>R. Basha & G.P. Nagaraju</i>	
Review Article: CD151 and TGF-β in Colon Cancer Metastasis: Flavonoids and Their Targeted Delivery Systems	1
<i>R.R. Malla, D.B. Kundrapu, B. Priyamavada, & G.P. Nagaraju</i>	
Research Article: FKBP4-HSP90 Interaction in Colorectal Cancer: A Novel Therapeutic Target	11
<i>Y. Golivi, S.K. Behera, S. Peela, & A. Alam</i>	
Research Article: The Aromatase Gene rs10046 T>C Polymorphism Does Not Contribute to the Risk of Breast Cancer: A Meta-Analysis	23
<i>M. Patel, A. Mohammed, M.K.A.A. Razab, & L.V.K.S. Bhaskar</i>	
Research Article: Immunogenic Cell Death-Related Gene Expression Signatures in Breast Cancer Subtypes: A TCGA- and GEO-Based Analysis with Potential Therapeutic Implications	33
<i>F. Marius & R.R. Malla</i>	
Research Article: <i>In Silico</i> Identification of Potential Inhibitors Targeting NUSAPI, A Hub Gene in Hepatocellular Carcinoma	53
<i>K. Dinesh, I.P. Gudivada, & K.C. Amajala</i>	
Review Article: Immunotherapy for Pediatric Malignancies: Benefits and Beyond	69
<i>S.S. Krishnan, J.A. Ayariga, N. Prakash, R.R. Gangavarapu, M. Sreepriya, & G.P. Nagaraju</i>	
Review Article: Efficacy and Safety of JNK Inhibitors in Cancer Therapy	91
<i>L.S. Sahithi, P. Nuthalapati, M.F. Hussain, S.N. Nagabhishek, B. Umeza, S.D. Roopa, A.A.K. Khan, & M.K. Ghanta</i>	

ISSUE 4

SPECIAL ISSUE: SPECIAL ISSUE: TRANSCRIPTION FACTOR AND TUMORIGENESIS

GUEST EDITOR: VIVI KASIM

Benjamin Bonavida Bio	v
Vivi Kasim Bio	vii
Preface: Transcription Factor in Tumorigenesis: Its Complex Roles and Therapeutic Potential <i>V. Kasim</i>	ix
Review Article: β-Catenin-Driven Cancer Stemness in Colorectal Cancer: Molecular Targets and Therapeutic Opportunities <i>M. Okotel & C. Huang</i>	1
Research Article: The Dysregulated YY1-Bcl-2-c-Myc Axis in Non-Hodgkin Lymphoma: Validation by Bioinformatic Analyses <i>M.P. Ho, E. Skouradaki, E. Otumo, S. Baritaki, & B. Bonavida</i>	21
Review Article: Decoding the Role of PBX3 in Cancer: Molecular Mechanisms and Therapeutic Strategies <i>S. Jaan, L. Zhang, V. Kasim, & S. Wu</i>	33
Review Article: YY2 in Tumor Regulation: Core Mechanisms and Functional Networks <i>Y. Li, L. Tang, X. Jia, & S. Wu</i>	49
Review Article: EZH2 in Pancreatic Cancer: Epigenetic Driver and Therapeutic Target <i>T. Festekdjian & B. Bonavida</i>	59
Review Article: Dynamin-Related Protein 1 in Cancer Progression: Mechanisms and Implications <i>M. Wei, Y. Liu, J. Liu, & S. Wu</i>	71
Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas <i>I. Navasardyan, S.Y. Lim, & J.G. Crompton</i>	85
Transcription Factor and Tumorigenesis: Perspectives and Concluding Remarks <i>V. Kasim</i>	95
Index, Volume 30, 2025	98

CRITICAL REVIEWS™ IN ONCOGENESIS

AUTHOR INDEX VOLUME 30, 2025

Page Range of Issues:

Issue 1: 1–135; Issue 2: 1–106; Issue 3: 1–108; Issue 4: 1–97

Alam, A., 11, 31	Jia, X., 49	Panda, A.K., 91
Amajala, K.C., 53	Kalpana, 43	Patel, M., 23
Ayariga, J.A., 69	Kasim, V., vii, ix, 33, 95	Peela, S., 11, 31
Baritaki, S., 21	Katiyar, P., 43	Prakash, N., 69
Basha, R., vii, xi	Khan, A.A.K., 91	Priyamavada, B., 1
Behera, S.K., 11, 31, 91, 119	Krishnan, S.S., 69	Rajakumari, S., 1, 107
Bhaskar, L.V.K.S., 23	Kumar, S., 91	Rathod, R., 91
Bonavida, B., v, xi, 21, 23, 37, 49, 59	Kumari, R., 91	Razab, M.K.A.A., 23
Crompton, J.G., 85	Kumari, S., 1	Roopa, S.D., 91
Cultrera, G., 83	Kundrapu, D.B., 1	Saddala, M.S., 59
Dinesh, K., 53	Leyva, B.K., 49	Sahithi, L.S., 91
Falzone, L., vii, xi, 67, 83	Li, Y., 49	Saritha, K.V., vii, xi, 1, 107
Fenga, C., 67	Libra, M., ix, xi, 83	Singh, C.M., 43
Festekdjian, T., 59	Lim, S.Y., 85	Skouradaki, E., 21
Franco, S., 83	Liu, J., 71	Spoto, G., 83
Gangavarapu, R.R., 69	Liu, Y., 71	Sreepriya, M., 69
Ghanta, M.K., 91	Malla, R.R., 1, 33, 71	Srilatha, M., 1
Ghava, D., 91	Marconi, A., 67	Srivastava, A., 43
Golivi, Y., 11, 31	Marius, F., 33	Tang, L., 49
Gudivada, I.P., 53	Matera, S., 67	Umeza, B., 91
Gupta, M.K., 15	Mohammed, A., 23	Ung, W., 23
Gupta, N., 119	Mundla, S., 59	Uppathi, P., 1, 107
Ho, M., 37	Nagabhishek, S.N., 91	Vadde, R., 15
Ho, M.P., 21	Nagaraju, G.P., ix, xi, 1, 69	Vempati, R.K., 71
Huang, C., 1	Navasardyan, I., 13, 85	Vivarelli, S., 67
Hussain, M.F., 91	Nuthalapati, P., 91	Wei, M., 71
Jaan, S., 33	Okotel, M., 1	Wu, S., 33, 49, 71
	Otumo, E., 21	Zhang, L., 33

CRITICAL REVIEWS™ IN ONCOGENESIS

SUBJECT INDEX VOLUME 30, 2025

Page Range of Issues:

Issue 1: 1–135; Issue 2: 1–106; Issue 3: 1–108; Issue 4: 1–97

- adenomatous polyposis coli, 91
ALL, 13
anti-cancer, 1
apoptosis, 91
apoptotic evasion, 33
bacterial translocation, 49
Bcl-2, 21
BiP, 33
breast cancer, 1, 23, 33, 37, 43, 67, 107
cancer stem cell, 49
cancer stem cells, 71
cancer stemness, 1
cancer, 21, 23, 31, 49, 59, 91
checkpoint inhibitor blockade, 37
checkpoint inhibitors, 23
chromatin instability, 49
circadian rhythms, 67
c-Jun N-terminal kinases, 91
CLEC7A, 119
clinical implications, 49
clinical trials, 23
c-Myc, 21
colon cancer, 1
colorectal cancer, 1, 11
combinatorial drug, 31
computation technique, 1
computational approaches, 43
coralyne, 71
CYP19A1, 23
cytotoxicity, 71
data variability, 15
distant tumors, 83
docking, 71, 107
DRP1, 71
drug design, 1
drug discovery, 91
drug likeliness, 53
drug resistance, 71
drug-target interaction, 1
dysbiosis, 67, 83
dysregulated axis, 21
enzimidazole, 43
epigenetics, 59
EPS, 119
exosomes, 1
EZH2, 59
fecal microbiota transplantation, 23
ferroptosis, 71
FKBP4, 11
flourouracil, 31
Fusobacterium nucleatum, 83
Ganetespi, 31, 91
genetic polymorphism, 23
glucose-6-phosphate dehydrogenase, 59
Grangea maderaspatana, 107
gut microbiome, 13, 67
gut microbiota, 1, 49
heat shock protein 90, 11, 31
hepatocellular carcinoma, 53
HER2+ subtype, 37
hormone-related cancers, 49
ICB, 37
ICIs, 37
imatinib, 119
immune checkpoint inhibitor, 37
immune checkpoints, 69
immune system modulators, 69
immunogenic cell death, 33
immunotherapy, 1, 23, 37, 49, 69
inhibitor, 59
inhibitors, 31
intratumoral immunotherapy, 85
JNK inhibitors, 91
lead compounds, 53
machine learning, 15
melanoma, 23
meta-analysis, 23
metabolic reprogramming, 49, 71
metastasis, 1, 33, 71
microbiome, 1, 49
mitochondrial fission, 71
mitogen-activated protein kinases, 91
MMP9, 71
molecular docking, 1
molecular dynamic simulations, 71
molecular target, 43
molecular targets, 1
neuroblastoma, 15
night shift work, 67
NUSAP1, 53
occupational health, 67
oncogenesis, 49
oral cancer, 83
oral microbiota, 83
pancreatic cancer, 59
PDB-1M17, 107
PD-L1 & PD-1, 37
pediatric cancer, 13
pediatric cancers, 69
pentose phosphate pathway, 59
personalized treatment, 15
pharmacokinetic properties, 107
Porphyromonas gingivalis, 83
pre-B-cell leukemia homeobox 3, 33
probiotics, 13, 23, 37, 49
proliferation, 71
protein–protein interactions, 11
Pseudolagarobasidium accaciicola, 119
quercetin, 1
resistance, 21, 59
risk prediction, 15
rs10046, 23
rutin, 1
sarcoma, 85
targeting, 59
taxifolin, 1
therapeutic, 59
therapies, 1
therapy, 21, 59
toxicity, 1
tumor immunity, 49
tumor microenvironment, 49, 85
tumor proliferation, 33
tumorigenesis, 33
unfolded protein response, 33
virtual screening, 53
Wnt signaling pathway, 91
Wnt/ β -catenin signaling pathway, 1
Yin Yang 2, 49
YY1, 21
 β -catenin, 1, 91
 β -glycan, 119